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Abstract: Salsolinol (1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline) is thought to regulate dopa-
minergic neurons and to act as a mediator in the neuroendocrine system. We have previously reported that 
exogenous salsolinol evokes enteric neuronal cell death, leading to the impairment of myenteric neurons 
density and abnormal intestinal transit in rats. We also observed significant reduction of body weight, relat-
ed to the disrupted gastrointestinal homeostasis.
The aim of current study was to evaluate the influence of prolonged salsolinol administration body weight, food 
intake, adipose tissue accumulation and fad pad adipocyte morphological parameters assessed by image analysis.
Male Wistar rats were subjected to continuous intraperitoneal low dosing of salsolinol — 200 mg/kg in 
total with ALZET osmotic mini-pumps (Durtec, USA) for 2 or 4 weeks with either normal or high-fat diet. 
Appropriate groups served as the controls. Food intake, body weight were measured each morning. Both 
epididymal fat pads were dissected, weighted and processed for routine hematoxylin and eosin staining. 
The following parameters: cell area, perimeter, long and short axis, aspect ratio and circularity factor were 
assessed in stained specimens with the image analysis system (Multisoft, Polska).
Salsolinol administration significantly reduced total body mass with no differences in total food intake be-
tween the groups. The epididymal fat pad weight over final body mass ratio was lower in salsolinol treated rats 
on high fat diet in comparison with the control groups. The area, perimeter, short and long axis of the fad pad 
adipocytes were significantly decreased in salsolinol treated animals in comparison with relevant controls.
Salsolinol targets some regulatory mechanisms concerned with the basic rat metabolism. Prolonged periph-
eral salsolinol administration in rats significantly decreases the adipocyte size, and such effect is related to 
the weight loss and reduced adipose tissue accumulation. 
Key words: salsolinol, rat, epididymal fat pad, weight loss, adipocyte area, image analysis, morphometry, 
osmotic minipumps.
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Introduction
In Parkinson’s disease (PD) patients, a broad spectrum of non-motor symptoms have 
been reported, which in some circumstances may precede motor impairment. These 
symptoms include weight changes and gastrointestinal dysregulation, such as dysphagia, 
delayed gastric emptying, nausea, constipation and faecal incontinence [1]. Weight loss 
is frequent in patients with Parkinson’s disease. Dysphagia, anorexia, sense of smell and 
appetite loss as well as gastrointestinal dysfunction may be possible causes of reduced 
energy intake; while rigidity, tremor, and levodopa-induced dyskinesia may increase en-
ergy expenditure. Moreover, some drugs e.g. levodopa may enhance glucose metabolism 
resulting in enhanced energy expenditure. Depression, antiparkinsonian drugs, medical 
complications such as pneumonia and malignancies may also facilitate weight loss in PD. 
Weight loss is associated with malnutrition and may precipitate infection, accelerate 
motor, behavioral and autonomic impairment in PD patients [2–4]. The mechanisms 
of weight loss in these patients, however, remain poorly understood.
In order to elucidate the possible mechanisms leading to weight loss in parkinso-
nian-like degenerations, we conducted previously few experimental studies using exog-
enously administrated salsolinol in rats [5–8]. 
The catechol isoquinoline derivatives are compounds widely present in the mam-
malian brain and the most investigated one is referred to as salsolinol (1-methyl-6,7- 
dihydroxy-1,2,3,4-tetrahydroisoquinoline). It was detected for the first time in rat and 
human brain tissue samples [9, 10]. It exerts a wide range of effects on the catecholami-
nergic transmission and dopaminergic neurons. It has been documented that salsolinol 
can cause the release of stored catecholamines, the inhibition of catecholamine re-
uptake, the inhibition of monoamine oxidase, catechol-O-methyltransferase and tyrosine 
hydroxylase [11–13]. In addition, it has been implicated in the development of alcoholism, 
in the release of the hormone prolactin [14] and in the etiopathogenesis of Parkinson’s 
disease [15, 16]. Salsolinol can be either endogenously synthesized from dopamine and 
acetaldehyde by salsolinol synthase and alternatively, from dopamine and pyruvic acid [17] 
or delivered exogenously with food [18]. Various toxins, tetrahydroizochinolines among 
them, may easily cross the intestinal barrier and reach the intestinal, neural pathways, 
initiate the processes of neurodegeneration in enteric nervous system and subsequent-
ly, via dorsal motor nucleus of the vagus nerve (dmX), in the central nervous system. 
Uptake of exogenous substances from the extraneuronal space is known to occur at 
the axon terminal and such material is to be transferred to the cell soma via retrograde 
axonal transport. Lots of neuroactive substances are taken up this way, usually through 
receptor-mediated endocytosis by the presynaptic membrane of the next nerve cell in 
the neuronal chain. And, such a neurotropic constituent might induce conformational 
changes in normal α-synuclein molecules, provoking their aggregation and formation 
of Lewy Bodies [19].
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The vagus nerve consists of axons, which emerge from or converge onto three nuclei of 
the medulla, including the dorsal nucleus of vagus – which sends parasympathetic output 
to the viscera, especially the intestines. The vagus nerve contributes to the bidirectional 
communications between the gastrointestinal tract and central nervous system. Afferent 
neurons of the vagus nerve are important targets of gut hormones, particularly the hor-
mones involved in controlling food intake. Vago-vagal reflexes are involved in feeding 
homeostasis, making neuromodulation an attractive method for obesity treatment [20].
In animal models with vagal nerve stimulation (VNS) decreased food intake and 
weight loss are considered as the result of the stimulation of brain centers, the periph-
eral action of vagal stimulation via short cholinergic reflexes, and the combination of 
central and peripheral signals [21]. It is also hypothesized that the VNS decreases both 
food intake and body weight gain by mimicking the “satiety” signals transmitted from 
the gut to the brain, leading to the activation of the hypothalamic neurons that initiate 
the state of satiety. VNS also exerts anorexigenic effects on food intake and body weight 
gain in rats with high-fat diet-induced obesity [22–24].
Body weight, food intake and body fat content are regulated by multiple factors 
[20, 25, 26]. Despite fluctuations in the amount of food consumed, body weight remains 
stable within a relatively narrow range. Food intake together with body mass is controlled 
by both short- and long-term regulatory mechanisms [27]. Hypoglycemia increases food 
intake and stimulates vagal nerve activity [28]. Food transported into the stomach and 
duodenum activates both chemo- and mechanoreceptors. These signals are also transmit-
ted via the vagus nerve to the hind brain where they are integrated and play a major role 
in short-term regulation by limiting the size of the meal consumed [25]. The long-term 
control of food intake involves many mediators (ghrelin, leptin, nesfatin-1, orexins and 
neuropeptide Y) and structures (nucleus of the solitary tract, arcuate nucleus of vagus 
nerve and hypothalamus) [26].
Vagus nerve stimulation influences the brain centers controlling appetite, body weight 
and also the adipose tissue accumulation. In rodents, fat tissue is localized in different 
depots, and visceral fat accumulates in the epididymal fat pad. This visceral fat is well 
delimitated and easy to excise. Although the epididymal fat pad represents only a small 
portion of the total body weight, previous studies have shown that the epididymal fat 
pad weight calculated as a proportion of total body weight is highly correlated with 
total body fat in mice and rats [29–31]. Moreover, the caudal epididymal fat pad is un-
der strong hormonal and nervous regulation [32–34]. Significant reduction of fat pad 
weight in rats following long-term VNS has been previously reported [22–24]. When 
the body composition was altered by electrical vagus nerve stimulation; epididymal 
fat pad mass relative to body weight was significantly lower in rats that received VNS 
compared with control animals.
In our previous experiments, we applied salsolinol given peripherally and continu-
ously in rats to induce changes in the enteric nervous system, which might be similar 
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to those observed in PD patients. Surprisingly, we noted significant decrease in body 
weight of the animals during salsolinol exposure. We hypothesized that salsolinol given 
peripherally can diminish food consumption and body weight via vagus afferents since 
it targets vagus nerve fibers and other centers responsible for appetite controlling [5–7]. 
Furthermore, while lipid profile, postprandial blood glucose and hepatic enzymes levels 
remained indifferent, postprandial triglyceridemia was significantly lower in all salsoli-
nol-treated rats in comparison with the control, which might be related to disturbed 
absorption. We also suggested that diminished body weight gain and lower adipose 
tissue accumulation in salsolinol-treated animals were due to delayed gastric emptying 
together with disturbed gut function resulting in absorptive dysfunction. In the current 
study, we assessed the fat pad adipocytes morphological properties using image analy-
sis methods, in order to verify the influence of peripheral salsolinol administration on 
visceral fat accumulation in rats. 
Material and methods
Study protocol
Thirty-two adult male Wistar rats were studied. The animals were housed in individual 
cages. All animals were housed in the same optimal conditions, and food and water 
were provided ad libitum. During experiment, rats were fed with either standard diet 
(2.86 kcal/g, Labofeed, Poland) or with obesity-inducing high-fat diet (4.34 kcal/g, 
Bento Kronen Products, Belgium). The temperature was maintained at 23 ± 2°C, and 
animals were placed on a 12:12 h dark/light cycle. The Jagiellonian University Bioeth-
ical Committee approved the care and use of the animals (ethical approval number — 
67/2009). 
The detailed methods of salsolinol administration were described previously [5–7]. 
Briefly, rats were either subjected to continuous dosing of salsolinol or served as con-
trol. Salsolinol (salsolinol hydrochloride, Sigma, USA) in the total dose of 200 mg/kg 
was dissolved in 200 μL of 0.9% solution of salt and delivered by ALZET osmotic mini-
pumps (Durtec, USA) implanted intraperitoneally. Control groups were implanted with 
ALZET osmotic mini-pumps filled with physiological solution of salt. 
Prior to implantation rats were randomly divided into the following eight groups 
(n = 4 each): 1) rats subjected to continuous dosing of salsolinol for two weeks (delivery 
rate 0.5 µL/h, S1 group) and fed with standard diet throughout the entire experimental 
period; 2) rats subjected to continuous dosing of salsolinol for two weeks (delivery 
rate 0.5 µL/h, SF1 group) and fed with high-fat diet throughout the entire experimental 
period; 3) rats subjected to continuous dosing of salsolinol for four weeks (delivery rate 
0.25 µL/h, S2 group) and fed with standard diet throughout the entire experimental pe-
riod; 4) rats subjected to continuous dosing of salsolinol for four weeks (delivery rate 
0.25 µL/h, SF2 group) and fed with high-fat diet throughout the entire experimental 
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period; 5) a control group fed with standard diet for two weeks (C1 group); 6) a control 
group fed with high-fat diet for two weeks (CF1 group); 7) a control group fed with 
standard diet for four weeks (C2 group); 8) a control group fed with high fat-diet for four 
weeks (CF2 group). Rats were starved for 12 hours and operated under general anesthe-
sia induced with sodium pentobarbital given intraperitoneally at a dose of 0.25 mg/kg 
(Vetbutal, Biowet, Poland).
During the study, daily food intake and body weight were measured each morning. 
At the end of the experiment (day 15 or 29, respectively), animals were euthanized by 
decapitation and both epididymal fat pads, located between the cauda epididymis and 
the distal extremity of the testis, were dissected from each rat and weighed. The epi-
didymal fat pad/body weight ratio was calculated by dividing the fat pad weight by the 
final body weight.
Histological staining and morphometrical analysis
Fresh fat pad specimens were cut and rinsed thoroughly with PBS (phosphate-buffered saline, 
0.01 mol/L, pH = 7.4). Tissue samples were then fixed in 4% phosphate-buffered paraformal-
dehyde, routinely processed and embedded in paraffin. Serial sections were cut and mount-
ed on glass slides. The sections were deparaffinized in xylene, rehydrated through a graded 
series of alcohol, and transferred to PBS prior to staining. Histopathological examination 
and morphometrical analysis were performed after routine staining with hematoxylin and 
eosin (H&E). 
The adipocytes were analyzed semi-quantitatively under light AXIOPHOT micro-
scope (ZEISS, Germany) connected with ProgResC12 plus (Jenamed, Germany) CCD 
camera using image cytometry system (Multiscan v.18; Computers Scanning System, 
Warszawa, Poland). At least 100 cells were counted in each specimen. The following 
parameters were assessed: cell area, perimeter, long and short axis, aspect ratio AR (cal-
culated as the ratio of the largest diameter and the smallest diameter) and circularity 
factor f (calculated as follows: f = 4πA/P2; A — area, P — perimeter). 
All data were expressed as the mean and standard deviation (SD). The results were 
analyzed using a one-way analysis of variance (ANOVA) followed by a post hoc Tukey’s 
test. All statistical tests were performed using STATISTICA software package (StatSoft, 
Tulsa, USA). Statistical significance was set at p <0.05.
Results
Food intake, body weight gain and epididymal fat pad weight in rats after salsolinol 
administration are summarized in Table 1 and Table 2. 
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Table 1. Food intake, body weight gain and epididymal fat pad weight in salsolinol-treated (S1, SF1 — rats 
for two weeks and fed with standard or high-fat diet, respectively) and control rats (C1, CF1 — control rats 
fed with standard or high-fat diet, respectively). Asterisks (*) indicate significant differences between the 
salsolinol-treated and control groups, p <0.05. 
Group S1 C1 SF1 CF1
Total food intake (g) 340.4 ± 15.2 360.2 ± 24.6 238.7 ± 26.6 253.5 ± 36.3
Initial body weight (g)     253.7 ± 9.9     251.5 ± 9.1     243.2 ± 4.7     220.0 ± 9.4
Final body weight (g) 312.8 ± 14.1     334.0 ± 8.9 314.1 ± 19.8     318.0 ± 4.9
Body weight gain (g)   59.1 ± 5.9*       81.6 ± 2.7     70.9 ± 18.2*       98.0 ± 13.9
Epididymal fat pad 
weight (EFP) (g)   3.4± 0.3   3.8± 0.4     4.1± 0.4*   5.1± 0.2
Table 2. Food intake, body weight gain and epididymal fat pad weight in salsolinol-treated (S2, SF2 — rats 
for four weeks and fed with standard or high-fat diet, respectively) and control rats (C2, CF2 — control rats 
fed with standard or high-fat diet, respectively). Asterisks (*) indicate significant differences between the 
salsolinol-treated and control groups p <0.05.
Group S2 C2 SF2 CF2
Total food intake (g) 644.3 ± 55.1 696.9 ± 39.1 429.3 ± 36.3 509.3 ± 24.1
Initial body weight (g) 23.9 ± 4.9 232.5 ± 11.9     234.2 ± 8.5     225.7 ± 7.6
Final body weight (g) 351.1 ± 33.5 366.8 ± 18.4 331.8 ± 24.9 387.5 ± 17.9
Body weight gain (g)       98.3 ± 30.5* 120.4 ± 19.7       97.6 ± 28.9* 161.8 ± 13.8
Epididymal fat pad 
weight (EFP) (g)   3.7± 0.5   5.1± 0.5     4.9± 1.3*   7.8± 1.0
Salsolinol did not influence the mean food consumption in both — 14 days and 28 
days treated groups. However the mean weight gain was significantly diminished in the 
salsolinol-treated groups of rats. Similarly, the epididymal fat pad weight, which reflects 
visceral body fat content, was significantly diminished in the salsolinol-treated groups 
compared with the relevant controls: SF1 vs. CF1 (p = 0.032) and similarly SF2 vs. CF2 
(p = 0.0007). There were no significant EFP differences between both salsolinol-treated 
groups of animals: group S1 vs. group SF1 and group S2 vs. group SF2.
The results of morphological analysis of the fat pad adipocytes measured in rats 
after salsolinol administration are presented in Table 3 and Figs 1 and 2. Fig. 3 shows 
fad pad adipocytes in hematoxylin and eosin stained specimen of the fat pad adipose 
tissue after two weeks of chronic salsolinol administration. 
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Table 3. Adipocyte area, perimeter, long and short axis, aspect ratio AR and circularity factor f in salsoli-
nol-treated and control rats. All data are expressed as the mean and standard deviation (SD). Asterisks (*) 
indicate significant differences between the salsolinol-treated and control groups p <0.05. Groups: S2, SF2 — 
rats for four weeks and fed with standard or high-fat diet, respectively; C2, CF2 — control rats fed with 
standard or high-fat diet, respectively; S1, SF1 — rats for two weeks and fed with standard or high-fat diet, 
respectively; C1, CF1 — control rats fed with standard or high-fat diet, respectively.
Group Area Perimeter Long axis Short axis Aspect ratio Circularity
C1   1371.63±482.92  165.08±28.30 47.58±9.09   33.51±8.07 1.469±0.323 0.616±0.089
S1  1070.66*±387.65 144.86*±24.33  40.44*±8.17 29.21*±7.15  1.424±0.286 0.622±0.098
CF1  1687.66±734.04  195.58±41.69   54.18±13.07     34.75±10.55 1.638±0.427 0.533±0.132
SF1   997.13*±376.92 141.04*±24.30  40.36*±8.68 27.40*±6.60 1.525±0.420 0.616±0.108
C2   1077.41±357.57  154.26±25.27   44.61±10.72   25.01±6.40 1.856±0.511 0.563±0.100
S2   1218.23±506.31  153.20±30.35   45.67±10.67   30.68±7.82 1.537±0.372 0.632±0.117
CF2    1444.41±615.77  180.91±32.74   51.78±13.77   30.45±9.43 1.793±0.520 0.532±0.107
SF2 1277.09*±486.96 155.60*±23.69  46.44*±9.21   32.11±7.63 1.494±0.339 0.647±0.149
Fig. 1. Adipocyte area in salsolinol-treated and control rats. All data are expressed as the mean and standard 
deviation (SD). Groups: S2, SF2 — rats for four weeks and fed with standard or high-fat diet, respectively; 
C2, CF2 — control rats fed with standard or high-fat diet, respectively; S1, SF1 — rats for two weeks and 
fed with standard or high-fat diet, respectively; C1, CF1 — control rats fed with standard or high-fat diet, 
respectively.
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Fig. 2. Adipocyte perimeter in salsolinol-treated and control rats. All data are expressed as the mean and 
standard deviation (SD). Groups: S2, SF2 — rats for four weeks and fed with standard or high-fat diet, re-
spectively; C2, CF2 — control rats fed with standard or high-fat diet, respectively; S1, SF1 — rats for two 
weeks and fed with standard or high-fat diet, respectively; C1, CF1 — control rats fed with standard or 
high-fat diet, respectively.
High fat diet significantly increased mean cell area, adipocyte perimeter, long and 
short axis in comparison with control diet. The mean adipocyte area, adipocyte perim-
eter, long and short cell axis were significantly decreased in all salsolinol-treated rats 
in comparison with the relevant controls. There was no clear statistically significant 
difference between the salsolinol-treated and control groups in the aspect ratio AR and 
circularity factor f (Table 3).
Discussion
Adipocyte size reflects adipocyte physiology, increased size being associated with com-
promised metabolism and the detrimental effects of obesity and type 2 diabetes. Physi-
ological status of adipose tissue can be estimated by morphometric analysis. Examining 
cells by microscopy has long been a primary method for studying cellular function. Be-
sides available computational software are widely used for collecting data of numerous 
accurate measurements. 
Adipose tissue is essential for glucose metabolism and energy production. Its endo-
crine function is no less relevant and modulated by the size of adipocytes in the body. 
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Fig. 3. Fad pad adipocytes in hematoxylin and eosin stained specimen from the fat pad adipose tissue after 
two weeks of salsolinol treatment. (A, magnification 200×) and (B, magnification 400×).
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Adipocytes synthesize a number of cytokines and other bioactive molecules, together 
termed adipokines. In adipose tissue from obese animals or humans, several metabolic 
functions are subject to change with adipocyte size. These functions include storage and 
mobilization of lipids and secretion of both leptin and tumor necrosis factor a (TNF-α) [35]. 
This excess secretion has been hypothesized to cause insulin resistance. For this reason, 
no less important it is to measure essential parameters of adipocytes and compare it in 
different groups of subjects, than evaluate general distribution and amount of adipose 
tissue [36–38].
Quantifying the number and size of adipocytes in the development, deposition is 
essential in characterizing the phenotype of a given adipose tissue depot. Size of adipo-
cytes might be evaluated as a predictor of metabolic disorders (type 2 diabetes) and in the 
same time as a result of different gene expression. Phosphodiesterase 3B (PDE3B) gene 
expression is generally reduced in large adipocytes of obese, insulin-resistant mice [39]. 
In cases of chronic positive energy imbalance adipocytes store surplus energy as tria-
cylglycerols, expanding in cell size (hypertrophy) and in cell number (hyperplasia) as 
a consequence [40, 41]. Adipocyte hypertrophy results from a relative increase in lipid 
deposition versus lipolysis. 
Despite in most studies the adipocyte size was observed, it is not clear known 
whether the function of adipose tissue cells vary with its size. In 1972 Salans et al. made 
an attempt to separate human adipocytes of different sizes from the same adipose tis-
sue sample by exploiting differences in the flotation rates of large and small fat cells. 
Complicated analysis of different cells showed that triglyceride turnover increases with 
adipocyte size [42–44]. 
Methods that allow quick and factual determination of adipocyte size are important 
to studies of metabolism. Despite, not exists “gold standard” for adipocyte size measure-
ment. Each methods has own positive and negative sights which might have an impact 
on results. In addition, no one of methods directly quantifies cell volume, which is the 
most significant predictor of endocrine function of adipocytes and also accurate pa-
rameter of cell size [37, 45]. 
The measurement of adipocyte size by microscopy is widely used, although the 
method is tedious and time consuming. Also manual techniques demand discrimina-
tion, counting and measurement of many hundreds of irregular events. This limits the 
number of fields that may be accurately counted in a timely fashion. More recently, 
manual quantification has been superseded by computational methods. Nowadays sev-
eral programs for computer image analysis are available: STEPanizer (web-based tool), 
Adiposoft, CellProlifer etc. All of them are fully automated open-source software for 
the quantification of adipocyte cellularity in histological sections. All measurements are 
faster and independently of the user, thus providing more objective results than manually 
based methods [42, 45, 46]. The “interactive” methods and systems, however requiring 
the time consuming personal supervision, are still quite popular.
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The most popular parameters usually estimated by microscopy with different magni-
fication are adipocyte area, perimeter, volume, length and width (the major and minor 
axes of adipocytes) and shape factors. Human fat cells can change ~20-fold in diameter 
and several thousand-fold in volume [47]. Thus, relevant reference specimens and control 
groups are extremely important to obtain reliable morphometrical data.
In humans and lower mammals, fat is stored in the adipose tissue in various loca-
tions within the body such as intraabdominal depots around the omentum, intestines, 
and perirenal areas, as well as in subcutaneous depots in the buttocks, thighs, and 
abdomen. In addition, WAT (white adipose tissue) can be found in many other areas, 
including in the retro-orbital space, face and the bone marrow [48]. Adipose tissue is 
made principally of white adipocytes, which are the primary site of triglyceride/energy 
storage, but also brown adipocytes (brown adipose tissue – BAT), which are import-
ant in both basal and inducible energy expenditure in the form of thermogenesis [49] 
White and brown adipose tissues are regulated by multiple hormonal and neural mech-
anisms, thus they constitute a great point of interest for studying obesity and metabolic 
disorders. Although the epididymal fat pad represents only a small portion of the total 
body weight, previous studies have shown that the epididymal fat pad weight calculat-
ed as a proportion of total body weight is highly correlated with total body fat in mice 
and rats [29–31]. In addition to adipocytes, fat pads contain preadipocytes, vascular 
cells, nerves, macrophages, and fibroblasts. It has been shown the direct innervation of 
white adipose tissues by both sympathetic (SNS) and parasympathetic nervous system 
(PNS). Bartness et al. have shown direct neuro-anatomical contact of nerves to white 
adipose tissue [33, 50–52]. There are many reports regarding the influence of SNS onto 
the number and size of the adipocytes by proliferation and differentiation of white and 
brown adipocytes [53]. Kreier et al. have shown for the first time innervation to various 
different fat pads (retroperitoneal, mesenteric, epididymal, and subcutaneous inguinal 
fat) by nervus vagus [34], what can partly explain the weight changes of epididymal fat 
pad after performed vagotomies or other manipulations on the vagus nerve and the 
impact of the VNS on fat content can be one of mechanisms of VNS effect on weight 
loss [22–24]. 
In our experiment high fat diet significantly increased mean cell area, adipocyte 
perimeter, long and short axis in comparison with control diet. But the mean adipocyte 
area, adipocyte perimeter, long and short cell axis were significantly decreased in all 
salsolinol-treated rats in comparison with the relevant controls. 
There are existing data of the decrease of adipose tissue in the patients with Par-
kinson’s disease, and the reason of this decrease is unknown. In the experiments on 
rats Kuranuki et al. have stated, that epididymal and retroperitoneal fat and total in-
tra-abdominal fat weights, expressed relatively to body weight, were significantly lower 
in the PD rats, treated with 6-OHDA group, than in the control group. This decreased 
intra-abdominal fat mass might be associated with lower insulin levels, which reduces 
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lipogenesis [54]. Meng et al. searching for the explanation of the reason for the adipose 
tissue decrease, in their experiments on rats with the PD model induced by 6-OHDA, 
have stated that retroperitoneal white adipose tissues weight and adipocyte surface area 
were significantly reduced in comparison to control rats. Their study demonstrates that 
degenerated dopaminergic neurons in the nigrostriatal system correlate with increases 
in sympathetic nervous system function, resulting in lipolysis and inhibition of fat cell 
differentiation [55].
Little is known about the general influence of salsolinol on short-term lipids’ and 
carbohydrates’ absorption, their utilization as well as on body weight and energy storing.
Kurnik et al. [5, 7] reported decrease in body weight and alteration in body fat 
contents of the animals during chronic peripheral salsolinol exposure. While lipid 
profile, postprandial blood glucose and hepatic enzymes levels remained indifferent, 
postprandial triglyceridemia was significantly lower in all salsolinol-treated rats in 
comparison with the control. Epididymal fat pad and body weight ratio were also sig-
nificantly diminished in salsolinol-treated rats compared to the control animals. This 
observation correlated with results of the body weight assessment. Although salsolinol 
treated animals consumed similar amount of food there was significant decrease in 
body weight gain in animals exposed to salsolinol. Therefore, author concluded that 
salsolinol may not influence the appetite regulating mechanism and the reduction of 
body weight was due to others, probably peripheral effects. Diminished body weight 
gain and lower adipose tissue accumulation in salsolinol-treated animals were due to 
delayed gastric emptying together with disturbed gut functions resulting in absorptive 
dysfunction [5, 7]. 
The results from current study confirm these observations. We showed that chronic 
peripheral salsolinol administration significantly decreases the adipocyte size, and such 
effect is related to weight loss and reduced adipose tissue accumulation in rats. 
We might speculate that absorptive dysfunction, rather peripheral than central in 
origin, resulted from delayed gastric emptying together with disturbed colon function, 
might be responsible for diminished body weight gain and slower adipose tissue accu-
mulation in salsolinol-treated animals, but further evidence is needed to support this 
postulate. 
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